This is out Library. Please click on the article title to view the details.
submitted by: admin on 05/07/2015
Both Germany and France have taken Actos off the market because of an increased risk of getting bladder cancer. The US is taking no action. Global sales of Actos are in the vicinity of $5 billion annually. All three "glitazone" drugs for type 2 diabetes have a poor track record. Rezulin was taken off the market more than a decade ago because it caused...
submitted by: admin on 05/07/2015
Drugs that increase the sensitivity of insulin in theory should be effective in preventing and treating type 2 diabetes. However, the glitazone drugs have turned out to have serious side effects that limit their use in clinical practice. The drug, Actos, is the one glitazone that could possibly be safe and effective in both the prevention and treatment...
submitted by: admin on 10/11/2013
The Journal of the National Cancer Institute in August published an article showing that both Avandia and Actos increase bladder cancer by more than 400% compared to baseline incidence in diabetics. These drugs account for more than 20% of all drugs used to treat type 2 diabetes. Actos ranks 9th in the sales of all pharmaceutical drugs. This is remarkable...
submitted by: admin on 12/22/2024
NEEDS TEXT AND KEYWORDS